Results 91 to 100 of about 26,226 (199)

Efficacy and safety of fondaparinux in elective total hip arthroplasty and hip fracture surgery: a systematic review and meta-analysis

Journal of Orthopaedic Surgery and Research
Background As life expectancy increases, the incidence of hip fractures and the demand for total hip arthroplasties (THA) are expected to rise. This demographic shift poses significant challenges, particularly in managing post-operative complications ...
Gonzalo Mariscal, Francisco José Tarazona-Santabalbina, Oliver Marin-Peña, Erika Rotavista, Sara Arroyo Martín, María Estrella Fernández de Sevilla, Jesús Gómez-Vallejo   +6 more
doaj   +1 more source

Extended prophylaxis with fondaparinux versus enoxaparin against venous thromboembolism [PDF]

, 2004
Patients undergoing major orthopaedic surgery face considerable risk of venous thromboembolic complications (VTE). This paper presents cost-effectiveness analysis of extended prophylaxis with fondaparinux and enoxaparin in patients undergoing hip ...
Bjorvatn, Afsane
core  

The use of fondaparinux in pregnancy [PDF]

British Journal of Haematology, 2014
Esra, Elsaigh, Jecko, Thachil, Michael J, Nash, Clare, Tower, Charles R M, Hay, Sian, Bullough, Louise, Byrd   +6 more
openaire   +2 more sources

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients

, 2004
Fondaparinux efficacy for thromboprophylaxis was evaluated in predefined high-risk hip fracture patients. Patients received fondaparinux 2.5 mg for 7 days following surgery; 656 patients were randomized double blind to receive placebo or continue ...
Colwell, C. W., Jr., Eriksson, Bengt I.,, Lassen, M. R.   +2 more
core  

Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study

, 2011
Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646 ...
Lagarce F, Tessier-Marteau A, Thomas O, Ramadan A, Benoit JP, Saulnier P, Legras P, Macchi L   +5 more
core  

Fondaparinux in the initial and long-term treatment of venous thromboembolism

, 2015
BACKGROUND: Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice.
Pagán, B., Villalobos, A., Falgá, C., Del Molino, F., Tzinieris, I., Ruiz Giménez, N., Vivero, F., Lorenzo, A., PRANDONI, PAOLO, Jara Palomares, L., González, J., Barba, R., Merah, A., Del Toro, J., Rivas, A., Hernández Huerta, S., Apollonio, A., Vela, J., Pesavento, R., Lecumberri, R., Rota, L., García Bragado, Fernando, Guida, A., Verhamme, P., Sousa, M. S., Ruiz, J., Dentali, F., Bascuñana, J., Moustafa, F., Braester, A., Mangiacapra, Sara, González Marcano, D., Gómez, V., Gallego, P., Bosevski, M., López Sáez, J. B., Prandoni, P., Font, L., Bounameaux, H., Lobo, J. L., Marchena, P. J., Maida, R., Calanca, L., Jaras, M. J., Trujillo Santos, J., Pesavento, Raffaele, Rosa, V., Barillari, G., Farge Bancel, D., Pasca, S., Amitrano, Maria, Madridano, O., Hernández, L., Mesquita, P., Soto, M. J., Samperiz, A., Ciammaichella, M., Enea, I., Visonà, A., Trujillo Santos, Javier, López Jiménez, Luciano, Nauffal, D., Piovella, Chiara, Monreal, Manuel, Lorente, M. A., Porras, J. A., Peris, M. L., Casado, I., De Ancos, C., Brenner, B., Tiraferri, E., Chaves, E. L., Falgá, Conxita, Morales, M. V., Valle, R., Amitrano, M., Malý, R., García Bragado, F., Pedrajas, J. M., López Jiménez, L., López Reyes, R., Tirado, R., Quere, I., Gutiérrez, J., Arcelus, J. I., Salgado, E., Zeltser, D., Serrano, J. C., Ribeiro De Almeida, J. L., Puerta, P., Farfán, A. I., Peerlinck, K., Papadakis, M., Tiberio, G., Benítez, J. F., Di Micco, P., Luque, J. M., Núñez, M. J., Matías, V., Mahe, I., Piovella, C., Alvarado, A. V., Guijarro, R., Hirmerova, J., Hij, A., Riera Mestre, A., Valero, B., Adarraga, M. D., Conget, F., Rodríguez Dávila, M. A., Barrón, M., Monreal, M., Pons, I., Babalis, D., Di Micco, Pierpaolo, Fernández Capitán, C., Mazzolai, L., Suriñach, J. M., Bura Riviere, A., Mellado, M., Román, P., Pace, F., Sánchez, R., Tilvan, R. M., Zdraveska, M., Tufano, A., Tzoran, I., Soler, S., Blanco Molina, A., Jiménez, D., Nieto, J. A., Barrón Andrés, B., Uresandi, F., Malfante, P., Bertoletti, L., Otero, R., Alatri, A., Grau, E., Wells, P., Schellong, S., Martín Antorán, J. M., López Montes, L., Cannavaccioulo, F.   +142 more
core   +1 more source

Surveillance biologique des héparines et du fondaparinux

, 2011
Anticoagulation with unfractionated heparin, low molecular weight heparin or fondaparinux is common practice in thromboembolic disease, atrial fibrillation and mechanical heart valves.
Boehlen, Françoise, Beauverd, Yan, Louis Simonet, Martine, Fontana, Pierre   +3 more
core  

Fondaparinux [PDF]

, 2020
openaire   +1 more source

Fondaparinux: A novel synthetic antithrombotic for prevention of venous thromboembolism

, 2001
Fondaparinux sodium is the first in a new class of antithrombotic medications called pentasaccharides. As a highly selective inhibitor of factor Xa, it leads to the inhibition of thrombin generation without a direct effect on thrombin itself ...
Feret, B.
core